Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Omeros Corporation is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel small-molecule and protein-based therapeutics targeting immunologic and complement-mediated diseases. The company operates primarily within the biotechnology and pharmaceutical research and development industries, with an emphasis on rare and orphan diseases with high unmet medical need.
The company’s core value proposition centers on its proprietary drug discovery platforms and its focus on the lectin pathway of the complement system, an area with limited approved therapies. Omeros was founded in 1994 and evolved from an academic research-focused enterprise into a publicly traded biopharmaceutical company following its initial public offering in 2009. Over time, the company transitioned away from commercial-stage ophthalmology products toward a pipeline-driven, immunology-focused strategy.
Business Operations
Omeros generates value primarily through the research and development of therapeutic candidates rather than through recurring product revenue. Its operations are centered on its lead monoclonal antibody narsoplimab (OMS721), a MASP-2 inhibitor being developed for multiple complement-mediated and inflammatory conditions. The company’s business model relies on advancing clinical programs toward regulatory approval, with potential revenue from future product sales, licensing, or strategic partnerships.
The company also controls proprietary platforms, including its GPCR (G protein–coupled receptor) discovery platform, which has historically been used to identify novel drug targets. Omeros conducts its research internally and through third-party clinical research organizations, with no material manufacturing operations of its own. Its primary wholly owned subsidiary is Omeros Subsidiary Corporation, which supports operational and intellectual property activities.
Strategic Position & Investments
Strategically, Omeros is focused on advancing narsoplimab across multiple indications, including thrombotic microangiopathies and other complement-driven disorders, while seeking regulatory pathways in both the United States and international markets. The company’s growth initiatives emphasize clinical differentiation through targeting the lectin pathway, which it positions as a strategic alternative to therapies that inhibit other complement pathways.
Omeros has historically invested heavily in internal R&D rather than large-scale acquisitions. It has entered into selective collaborations and licensing arrangements to support development and commercialization while retaining core intellectual property rights. The company continues to explore additional pipeline assets derived from its discovery platforms, though publicly available data on late-stage diversification remains limited.
Geographic Footprint
Omeros is headquartered in North America, with its principal executive offices located in Seattle, Washington. The company’s operational footprint is primarily U.S.-based, encompassing research, clinical development, and corporate functions.
Internationally, Omeros has clinical trial activities and regulatory engagement in Europe and other global regions as required for multinational studies. While it does not maintain a broad physical presence across continents, its development programs and intellectual property strategy are designed to support future global commercialization.
Leadership & Governance
Omeros is led by its founder, who has maintained a central role in shaping the company’s long-term scientific and strategic vision. The leadership team emphasizes scientific rigor, internal discovery capabilities, and disciplined advancement of high-impact therapeutic candidates.
Key executives include:
- Gregory A. Demopulos – President and Chief Executive Officer
- Karen L. Andersen – Senior Vice President, Clinical Development
- Arthur Tzianabos – Senior Vice President, Research
- Jeffrey S. Buchanan – Chief Financial Officer
- Mark W. Kinnel – Senior Vice President, Business Development
The company is governed by a board of directors with experience across biotechnology, medicine, and corporate governance, aligning oversight with its research-driven strategy.